A tracer originally designed to hunt prostate cancer is proving to be an unexpected ally in one of the world’s deadliest liver malignancies. In a prospective pilot study conducted at IRCCS Azienda Ospedaliero-Universitaria di Bologna, researchers led by Luigia Vetrone and Andrea Farolfi have demonstrated that gallium-68 labeled PSMA-11 positron emission tomography, a molecular imaging technique built around a protein called prostate-specific membrane antigen, not only detects hepatocellular carcinoma with striking sensitivity but also mirrors a biological feature of the tumor that pathologists can only see under the microscope: the expression of PSMA in the newly formed blood vessels that feed the cancer. The findings, published in the European Journal of Nuclear Medicine and Molecular Imaging, offer the most direct evidence yet that what a PSMA PET scanner sees in a living patient corresponds to what immunohistochemistry reveals in resected tissue, a validation step that could reshape how liver cancer is staged and, eventually, treated.
Hepatocellular carcinoma, the most common primary liver cancer, is a disease of stark contrasts. It is highly heterogeneous at the molecular level, yet for decades clinicians have had to rely on relatively blunt instruments to diagnose and characterize it. Contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging remain the workhorses of detection, supported by standardized frameworks such as the LI-RADS criteria, which score liver lesions on the basis of how they take up and wash out contrast agents. These tools are effective, but they describe anatomy and blood flow rather than the underlying biology of the tumor. For a cancer whose behavior, prognosis, and response to therapy depend heavily on the richness and molecular character of its vasculature, that is a significant blind spot. The Bologna team set out to test whether a molecular probe could fill it.
The probe in question, [68Ga]Ga-PSMA-11, binds to prostate-specific membrane antigen, a cell surface enzyme whose name betrays its origins in prostate cancer research but whose biology is far broader. In hepatocellular carcinoma, PSMA is not typically produced by the tumor cells themselves. Instead, it appears on the endothelial cells lining the tumor-associated neovasculature, the chaotic network of new blood vessels that cancers recruit to supply themselves with oxygen and nutrients. This neoangiogenic expression is precisely what makes PSMA an attractive imaging target in the liver: a radiolabeled ligand injected into the bloodstream should accumulate in the vessels of aggressive tumors, effectively painting a portrait of the tumor’s blood supply on a PET scan. Prior retrospective studies and meta-analyses had suggested PSMA PET could detect hepatocellular carcinoma, but the field lacked prospective data directly correlating scan intensity with tissue-level PSMA expression.
The Bologna study was designed to close that gap. The researchers enrolled patients with suspected hepatocellular carcinoma who were scheduled for curative-intent treatment, either surgical liver resection or liver transplantation. Thirty-nine patients were found eligible, of whom thirty-one ultimately underwent surgery. Every participant received both contrast-enhanced MRI and [68Ga]Ga-PSMA-11 PET/CT within a three-month window, ensuring that the two imaging modalities captured the disease at roughly the same point in its natural history. After surgery, the resected specimens underwent full histopathological analysis, including immunohistochemical staining for PSMA, allowing the investigators to compare, lesion by lesion, what the scanner had measured against what the tissue actually expressed. The study was approved by the local ethics committee and registered on ClinicalTrials.gov, and its prospective, monocentric design lends a methodological rigor that earlier retrospective reports could not provide.
The results are striking. Twenty-seven of the thirty-one surgically treated patients, or eighty-seven percent, showed visible PSMA uptake on PET/CT, with a median maximum standardized uptake value, or SUVmax, of 12.6 and an interquartile range spanning 10.2 to 16.5. To put those numbers in perspective, an SUVmax above ten is generally considered intense uptake in nuclear medicine practice, indicating that the tracer was concentrating avidly within the tumors. On the pathology side, immunohistochemistry told a matching story: PSMA was expressed in twenty-two of twenty-four evaluable hepatocellular carcinomas, a rate of 91.6 percent. The near-concordance between imaging positivity and tissue expression is the study’s central achievement, because it demonstrates that the tracer’s biodistribution in patients is not an artifact of blood pool activity or nonspecific accumulation but a genuine readout of molecular biology.
The most consequential statistical finding concerns the vasculature. When the team correlated semi-quantitative PET parameters with the immunohistochemical metrics, they found that high PSMA uptake on PET/CT correlated significantly with strong PSMA expression in the tumor-associated vasculature, with a p-value of 0.028. In practical terms, the brighter the tumor glowed on the scan, the more densely its feeding blood vessels expressed the target protein. This is more than a technical curiosity. PSMA expression in tumor-associated neovasculature has previously been linked to poor prognosis in hepatocellular carcinoma, meaning that a noninvasive scan capable of quantifying this feature could, in principle, stratify patients by aggressiveness before a scalpel is ever lifted. It also opens a theranostic door: the same target that can be imaged with gallium-68 can, in principle, be attacked with therapeutic radionuclides such as lutetium-177, an approach already established in PSMA-expressing prostate cancer.
Not every correlation held up, and the negative results are themselves informative. The researchers found no significant relationships between PET parameters and conventional histological features such as Edmondson grade, the standard scheme for grading how differentiated or anaplastic hepatocellular carcinoma cells appear, or the presence of vascular invasion, a key prognostic marker. All of these comparisons yielded p-values above 0.05. This dissociation suggests that PSMA PET is measuring something distinct from tumor grade or invasiveness, namely the molecular character of the tumor’s blood supply, rather than simply serving as a proxy for how aggressive the cancer cells look under the microscope. For a biomarker to earn its place in clinical practice, it must add information beyond what existing tools provide, and this independence from traditional histological grading may be exactly that added value.
The diagnostic performance of the technique in this prospective cohort adds to a rapidly growing literature. Earlier work by Hirmas and colleagues showed that Ga-PSMA-11 PET/CT improves tumor detection and impacts management decisions in hepatocellular carcinoma patients, while comparative studies have pitted PSMA PET against fluorodeoxyglucose PET, the workhorse tracer of oncological imaging, with PSMA agents generally performing better in the liver. Systematic reviews and meta-analyses, including a 2024 analysis by Hannah and colleagues, have consolidated evidence that PSMA PET/CT is a credible detection tool for hepatocellular carcinoma. What the Bologna study contributes is the prospective, histopathologically anchored confirmation that the scan’s signal has a defined biological substrate, addressing the fundamental question that has hovered over the field since the first serendipitous observations of liver uptake in prostate cancer patients.
The clinical implications extend to the theranostic frontier. If PSMA PET/CT can reliably map vascular PSMA expression before treatment, clinicians could potentially select patients whose tumors are most likely to respond to PSMA-targeted radioligand therapy, monitor changes in neovascular PSMA expression during treatment, and identify patients whose tumors lack the target altogether, sparing them futile therapy. The authors conclude that PSMA PET/CT offers robust diagnostic accuracy for hepatocellular carcinoma and correlates with vascular PSMA expression, supporting its potential utility in preoperative staging and justifying further exploration of PSMA imaging as a biomarker in this disease. As a pilot study with thirty-one surgical patients from a single center, the work is a beginning rather than an endpoint, and the investigators themselves frame it as such. Larger multicenter trials will be needed to confirm the correlations, establish standardized uptake thresholds, and determine whether vascular PSMA imaging can genuinely predict prognosis or guide therapy selection.
Nevertheless, the trajectory is unmistakable. A molecule discovered in the prostate gland, exploited for a decade to image prostate cancer with unprecedented precision, is now being validated as a window into the angiogenic biology of liver cancer, one of the leading causes of cancer death worldwide. The Bologna team’s prospective correlation of scanner signal with microscope truth represents the kind of translational bridge that molecular imaging requires before it can change guidelines, and it arrives at a moment when the hepatocellular carcinoma community is actively searching for biomarkers beyond conventional imaging. If subsequent studies replicate these findings, the humble PSMA ligand may soon be doing double duty in oncology departments: first as a diagnostic spotlight on liver tumors and their blood supply, and ultimately as the targeting beacon for radioactive payloads aimed at the very vessels that keep those tumors alive.
Subject of Research: Correlation of 68Ga-PSMA-11 PET/CT biodistribution with immunohistochemical PSMA expression in hepatocellular carcinoma
Article Title: Correlation of 68Ga-PSMA-11 PET/CT biodistribution with PSMA expression by immunohistochemistry in patients with HCC: A pilot prospective monocentric study
Article References: Vetrone, L., Prosperi, E., Prosperi, E., Vasuri, F., Degiovanni, A., Allegri, V., Castellucci, P., Zanoni, L., Nanni, C., Renzulli, M., Lucidi, V., Cattabriga, A., Malizia, C., Ravaioli, M., Cescon, M., Fanti, S., & Farolfi, A. (2026). Correlation of 68Ga-PSMA-11 PET/CT biodistribution with PSMA expression by immunohistochemistry in patients with HCC: A pilot prospective monocentric study. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08110-y
Image Credits: AI Generated
DOI: 10.1007/s00259-026-08110-y
Keywords: PSMA PET/CT, hepatocellular carcinoma, 68Ga-PSMA-11, molecular imaging, tumor neovasculature, immunohistochemistry, theranostics, liver cancer, SUVmax, preoperative staging, angiogenesis, nuclear medicine
Cite Scienmag News
APA
MLA
Chicago
Nathaniel Bowman. (October 2, 2026). Prostate Cancer Tracer Lights Up Liver Cancer Blood Vessels in Landmark Imaging Study. Scienmag. https://scienmag.com/prostate-cancer-tracer-lights-up-liver-cancer-blood-vessels-in-landmark-imaging-study/
Nathaniel Bowman. “Prostate Cancer Tracer Lights Up Liver Cancer Blood Vessels in Landmark Imaging Study.” Scienmag, 2 October 2026, https://scienmag.com/prostate-cancer-tracer-lights-up-liver-cancer-blood-vessels-in-landmark-imaging-study/. Accessed 2 October 2026.
Nathaniel Bowman. “Prostate Cancer Tracer Lights Up Liver Cancer Blood Vessels in Landmark Imaging Study.” Scienmag. October 2, 2026. https://scienmag.com/prostate-cancer-tracer-lights-up-liver-cancer-blood-vessels-in-landmark-imaging-study/
Copy citation
Download RIS
Tags: 68Ga-PSMA-11advancements in liver cancer diagnosisangiogenesisgallium-68 labeled PSMA in liver tumorshepatocellular carcinomaimaging biomarkersimmunohistochemistryinnovative imaging techniques for hepatocellular carcinomaliver cancerliver cancer staging with PSMA PETmolecular imagingmolecular imaging of tumor blood vesselsnovel applications of prostate-specific membrane antigennuclear medicinepreoperative stagingprostate cancer tracer for liver cancer detectionPSMA expression in cancer-associated blood vesselsPSMA PET/CTPSMA-11 PET imaging in hepatocellular carcinomaSUVmaxtargeted imaging of tumor vasculatureTheranosticstumor neovasculaturevalidation of PSMA PET with immunohistochemistry
